148 related articles for article (PubMed ID: 20207556)
1. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.
Prins RC; Rademacher BL; Mongoue-Tchokote S; Alumkal JJ; Graff JN; Eilers KM; Beer TM
Urol Oncol; 2012; 30(1):33-7. PubMed ID: 20207556
[TBL] [Abstract][Full Text] [Related]
2. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Beer TM; Lalani AS; Lee S; Mori M; Eilers KM; Curd JG; Henner WD; Ryan CW; Venner P; Ruether JD; Chi KN;
Cancer; 2008 Jun; 112(11):2377-83. PubMed ID: 18428198
[TBL] [Abstract][Full Text] [Related]
4. C-Reactive Protein is a Prognostic Marker for Patients with Castration-Resistant Prostate Cancer.
Liao SG; Cheng HH; Lei Y
Oncol Res Treat; 2016; 39(5):266-71. PubMed ID: 27174032
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel.
Ito M; Saito K; Yasuda Y; Sukegawa G; Kubo Y; Numao N; Kitsukawa S; Urakami S; Yuasa T; Yamamoto S; Yonese J; Fukui I
Urology; 2011 Nov; 78(5):1131-5. PubMed ID: 22054387
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.
Obata J; Kikuchi E; Tanaka N; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakagawa K; Oya M
Urol Oncol; 2013 Nov; 31(8):1725-30. PubMed ID: 23141922
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
11. Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer.
McCall P; Catlow J; McArdle PA; McMillan DC; Edwards J
Cancer Biomark; 2011-2012; 10(2):91-9. PubMed ID: 22430136
[TBL] [Abstract][Full Text] [Related]
12. Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases.
Nakashima J; Kikuchi E; Miyajima A; Nakagawa K; Oya M; Ohigashi T; Murai M
Urol Int; 2008; 80(2):129-33. PubMed ID: 18362480
[TBL] [Abstract][Full Text] [Related]
13. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of OCT4 expression in patients with prostate cancer.
Kosaka T; Mikami S; Yoshimine S; Miyazaki Y; Daimon T; Kikuchi E; Miyajima A; Oya M
Hum Pathol; 2016 May; 51():1-8. PubMed ID: 27067776
[TBL] [Abstract][Full Text] [Related]
15. Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients.
Graff JN; Beer TM; Liu B; Sonpavde G; Taioli E
Clin Genitourin Cancer; 2015 Aug; 13(4):e217-e221. PubMed ID: 25735198
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey.
Bittoni MA; Focht BC; Clinton SK; Buckworth J; Harris RE
Int J Oncol; 2015 Oct; 47(4):1537-44. PubMed ID: 26323323
[TBL] [Abstract][Full Text] [Related]
17. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ
Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165
[TBL] [Abstract][Full Text] [Related]
18. Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome.
Kälin M; Cima I; Schiess R; Fankhauser N; Powles T; Wild P; Templeton A; Cerny T; Aebersold R; Krek W; Gillessen S
Eur Urol; 2011 Dec; 60(6):1235-43. PubMed ID: 21741162
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
20. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Halabi S; de Wit R; Tannock IF; Eisenberger M
Prostate Cancer Prostatic Dis; 2009; 12(1):88-93. PubMed ID: 18574490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
